BIO – Bio-Rad Laboratories, Inc.
BIO — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
5.57
Margin Of Safety %
-13
Put/Call OI Ratio
0.1
EPS Next Q Diff
-0.02
EPS Last/This Y
-17.64
EPS This/Next Y
1.09
Price
265.4
Target Price
333.75
Analyst Recom
2.14
Performance Q
-12.05
Upside
131.4%
Beta
1.15
Ticker: BIO
16 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-02 | BIO | 279.68 | 0.08 | 0.00 | 836 |
| 2026-03-04 | BIO | 284.68 | 0.09 | 0.03 | 814 |
| 2026-03-05 | BIO | 278.98 | 0.09 | 0.02 | 802 |
| 2026-03-09 | BIO | 271.76 | 0.09 | 0.00 | 834 |
| 2026-03-10 | BIO | 267.93 | 0.09 | 999.99 | 835 |
| 2026-03-11 | BIO | 269.91 | 0.09 | 0.33 | 836 |
| 2026-03-12 | BIO | 261.87 | 0.09 | 0.50 | 838 |
| 2026-03-17 | BIO | 269.62 | 0.09 | 0.50 | 838 |
| 2026-03-18 | BIO | 268.09 | 0.09 | 0.00 | 841 |
| 2026-03-19 | BIO | 264.89 | 0.09 | 0.00 | 841 |
| 2026-03-20 | BIO | 264.4 | 0.09 | 1.00 | 834 |
| 2026-03-23 | BIO | 265.16 | 0.09 | 0.50 | 434 |
| 2026-03-24 | BIO | 272.36 | 0.10 | 0.20 | 437 |
| 2026-03-25 | BIO | 273.77 | 0.10 | 0.00 | 449 |
| 2026-03-26 | BIO | 276.66 | 0.10 | 0.00 | 450 |
| 2026-03-27 | BIO | 265.4 | 0.10 | 1.00 | 454 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
16 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | BIO | 278.25 | -22.0 | -752.5 | 10.27 |
| 2026-03-02 | BIO | 279.53 | -22.0 | -680.4 | 10.27 |
| 2026-03-03 | BIO | 280.12 | -22.0 | -680.8 | 10.27 |
| 2026-03-04 | BIO | 284.85 | -22.0 | -675.2 | 10.27 |
| 2026-03-05 | BIO | 278.95 | -22.0 | -690.9 | 10.27 |
| 2026-03-06 | BIO | 269.67 | -22.0 | -695.8 | 10.27 |
| 2026-03-09 | BIO | 271.81 | -27.0 | -684.6 | 10.23 |
| 2026-03-10 | BIO | 267.74 | -27.0 | -688.4 | 10.23 |
| 2026-03-11 | BIO | 269.81 | -27.0 | -681.6 | 10.23 |
| 2026-03-12 | BIO | 261.64 | -27.0 | -695.1 | 10.23 |
| 2026-03-13 | BIO | 262.74 | -27.0 | -684.7 | 10.23 |
| 2026-03-17 | BIO | 269.33 | -27.0 | -674.8 | 10.23 |
| 2026-03-18 | BIO | 268.09 | -27.0 | -685.9 | 10.23 |
| 2026-03-19 | BIO | 264.92 | -27.0 | -669.7 | 10.23 |
| 2026-03-20 | BIO | 264.28 | -27.0 | -667.1 | 10.23 |
| 2026-03-23 | BIO | 265.11 | -27.0 | -665.3 | 10.23 |
| 2026-03-24 | BIO | 272.12 | -27.0 | -655.6 | 10.23 |
| 2026-03-25 | BIO | 273.71 | -27.0 | -661.8 | 10.23 |
| 2026-03-26 | BIO | 276.61 | -27.0 | -659.4 | 10.23 |
| 2026-03-27 | BIO | 265.40 | -27.0 | -678.2 | 10.23 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
20 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | BIO | -0.01 | -2.84 | 5.26 |
| 2026-03-02 | BIO | -0.01 | -1.82 | 5.26 |
| 2026-03-03 | BIO | -0.01 | -1.82 | 5.26 |
| 2026-03-04 | BIO | -0.01 | -1.82 | 5.26 |
| 2026-03-05 | BIO | -0.01 | -1.82 | 5.26 |
| 2026-03-06 | BIO | -0.01 | -1.82 | 5.26 |
| 2026-03-09 | BIO | -0.01 | -1.73 | 5.26 |
| 2026-03-10 | BIO | -0.01 | -1.73 | 5.26 |
| 2026-03-11 | BIO | -0.01 | -1.73 | 5.24 |
| 2026-03-12 | BIO | -0.01 | -1.73 | 5.24 |
| 2026-03-13 | BIO | -0.01 | -1.73 | 5.24 |
| 2026-03-17 | BIO | -0.01 | -1.78 | 5.24 |
| 2026-03-18 | BIO | -0.01 | -1.78 | 5.24 |
| 2026-03-19 | BIO | -0.01 | -1.78 | 5.24 |
| 2026-03-20 | BIO | -0.01 | -1.78 | 5.24 |
| 2026-03-23 | BIO | -0.01 | -1.78 | 5.24 |
| 2026-03-24 | BIO | -0.01 | -1.78 | 5.24 |
| 2026-03-25 | BIO | -0.01 | -1.78 | 5.57 |
| 2026-03-26 | BIO | -0.01 | -1.78 | 5.57 |
| 2026-03-27 | BIO | -0.01 | -1.78 | 5.57 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
20 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
2.51
Avg. EPS Est. Current Quarter
1.85
Avg. EPS Est. Next Quarter
2.49
Insider Transactions
-0.01
Institutional Transactions
-1.78
Beta
1.15
Average Sales Estimate Current Quarter
587
Average Sales Estimate Next Quarter
659
Fair Value
230.81
Quality Score
93
Growth Score
38
Sentiment Score
74
Actual DrawDown %
68.1
Max Drawdown 5-Year %
-73.8
Target Price
333.75
P/E
9.51
Forward P/E
22.94
PEG
2.75
P/S
2.77
P/B
0.96
P/Free Cash Flow
19.12
EPS
27.92
Average EPS Est. Cur. Y
10.23
EPS Next Y. (Est.)
11.31
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
29.42
Relative Volume
1.22
Return on Equity vs Sector %
-17.2
Return on Equity vs Industry %
-1.6
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.04
EBIT Estimation
-678.2
◆
BIO
Healthcare
$265.40
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
20/20
Pullback
11/25
Volume
4/15
Valuation
17/20
TP/AR
1/10
Options
5/10
RSI
42.8
Range 1M
21.9%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
8/25
Growth
12/30
Estimates
3/20
Inst/Vol
3/15
Options
6/10
EPS Yr
3.3%
EPS NY
12.9%
52W%
41.1%
💎
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-1.8% upside
Quality
14/30
Valuation
4/30
Growth
9/25
Stability
7/10
LT Trend
3/5
Upside
-1.8%
Quality
93
MoS
-13%
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Medical Devices
Employees: 7450
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
BIO
Latest News
—
Caricamento notizie per BIO…
stock quote shares BIO – Bio-Rad Laboratories, Inc. Stock Price stock today
news today BIO – Bio-Rad Laboratories, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BIO – Bio-Rad Laboratories, Inc. yahoo finance google finance
stock history BIO – Bio-Rad Laboratories, Inc. invest stock market
stock prices BIO premarket after hours
ticker BIO fair value insiders trading